According to a new report by Patients for Affordable Drugs, Medicare spent an astonishing $46 billion on just two blood thinners between 2015 and 2020.
These are Xarelto by Johnson & Johnson and Eliquis by Bristol Myers Squibb and Pfizer. The list prices of these medications have more than doubled since their introduction to the market, posing a significant burden on the healthcare system and patients.
While list prices are not the final cost of medications after rebates and negotiations between drug manufacturers and payers, they hold significant weight. Particularly concerning is the impact of these rising list prices on Medicare Part D cost-sharing arrangements. Medicare beneficiaries are directly affected, as they have to pay more out of pocket when these list prices increase.
Blood thinners are far from a niche medication. Over 8 million Americans depend on them regularly to manage various conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Before 2010, warfarin was the go-to option for blood thinning. Though cost-effective, warfarin carries a substantial risk of heavy bleeding, making its use challenging to manage.
However, the landscape began to change in 2011, when Johnson & Johnson introduced Xarelto, followed by Eliquis in 2013. These new entrants promised a better safety profile, reducing the risk of severe bleeding associated with warfarin. However, the cost was significantly higher; while warfarin could be bought for a fraction of the price, these new drugs entered the market with list prices upwards of $200 for a month’s supply.
Over time, the list prices for both Eliquis and Xarelto have surged, and they now stand at over $500 for a month’s supply. While these medications offer advantages in terms of safety and efficacy, the price inflation remains a point of concern. By 2020, Eliquis became Medicare’s top-spending drug, and Xarelto was not far behind as the third-most costly. With nearly 4 million Medicare beneficiaries relying on one of these two drugs, the financial ramifications are hard to ignore.
The rising costs of these blood thinners can have a domino effect on healthcare expenditures and resource allocation. When the healthcare system is burdened with high medication costs, there could be less available for other essential services, diagnostics, and treatments. Moreover, exorbitant out-of-pocket costs could discourage patients from adhering to their medication regimens, risking complications that are costlier to manage in the long term.
The need for affordable yet effective medication is a pressing concern. The significant spending on blood thinners like Eliquis and Xarelto is a stark reminder that balancing drug innovation with affordability remains a critical challenge. As policymakers ponder over healthcare reforms, the findings by Patients for Affordable Drugs offer compelling evidence that change is not just desirable, but urgently needed.
Starting Sept. 1, 2024, a crucial change will occur in the way Medicare deals with high-cost blood thinners like Eliquis and Xarelto. Medicare will pay a negotiated rate for these drugs, a departure from the earlier model, which led to skyrocketing costs. While this is a step in the right direction, for users like myself who rely on Eliquis, the financial burden remains severe. With the existing rates, my insurance and I will still be facing a staggering cost of over $6,000 for my prescription.
While the decision to move to a negotiated rate is commendable, the question remains: is it enough? Again, the list prices for these drugs have more than doubled since their introduction to the market.
Given the scale of the problem, simply introducing a negotiated rate might not be a sufficient solution.
Imagine receiving notice that your healthcare organization faces a potential multimillion-dollar repayment demand based on the review of just 100 claims. This scenario, playing out
Some of you may have read my article from last week kindly published as a special bulletin. For those who did not, let me recap.
Please log in to your account to comment on this article.
Master the complexities of heart failure coding with this expert-led webcast by Emily Montemayor, CCS, CMBCS, COC, CPC, CPMA. Discover strategies to ensure compliance with ICD-10-CM guidelines, documentation integrity, and capture comorbidities like CKD and hypertension. Learn how to resolve coding challenges, improve documentation practices, and submit clean claims to minimize denials and safeguard your organization’s financial health. With practical insights and real-world examples, this session equips you to prevent revenue leakage, enhance compliance, and secure optimal reimbursement—all while supporting better patient outcomes.
Prepare your organization for the 2025 OPPS updates with expert insights from Tiffani Bouchard, CCS, CRCR, a Revenue Integrity Professional with over 30 years of experience. This webcast will address critical challenges in charge capture and coding, providing clarity on APC policies, C-APC packaging, exclusions, and payer-specific requirements. Attendees will learn actionable strategies to ensure compliance, optimize reimbursement, and mitigate risks of claim denials. Gain the knowledge needed to implement updates effectively, educate your team, and maintain seamless revenue cycle operations in the face of evolving OPPS complexities.
Join Beth Wolf, MD, CPC, CCDS, for an in-depth webcast on the FY2025 spinal fusion MS-DRG updates. Discover key changes in DRG classification, understand impacts on documentation and CMI, and learn strategies to ensure compliance.
Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.
Dr. Ronald Hirsch dives into the basics of Medicare for clinicians to be successful as utilization review professionals. He’ll break down what Medicare does and doesn’t pay for, what services it provides and how hospitals get paid for providing those services – including both inpatient and outpatient. Learn how claims are prepared and how much patients must pay for their care. By attending our webcast, you will gain a new understanding of these issues and be better equipped to talk to patients, to their medical staff, and to their administrative team.
Hospitals face growing challenges in measuring observation metrics due to inconsistencies in classification, payer policies, and benchmarking practices. Join Tiffany Ferguson, LMSW, CMAC, ACM, and Anuja Mohla, DO, FACP, MBA, ACPA-C, CHCQM-PHYADV as they provide critical insights into refining observation metrics. This webcast will address key issues affecting observation data integrity and offer strategies for improving consistency in reporting. You will learn how to define meaningful metrics, clarify commonly misinterpreted terms, and apply best practices for benchmarking, and gain actionable strategies to enhance observation data reliability, mitigate financial risk, and drive better decision-making.
The 2025 Medicare Physician Fee Schedule brings significant changes to payment rates, coverage, and coding for physician services, impacting practices nationwide. Join Stanley Nachimson, MS., as he provides a comprehensive guide to understanding these updates, offering actionable insights on new Medicare-covered services, revised coding rules, and payment policies effective January 1. Learn how to adapt your practices to maintain compliance, maximize reimbursement, and plan for revenue in 2025. Whether you’re a physician, coder, or financial staff member, this session equips you with the tools to navigate Medicare’s evolving requirements confidently and efficiently.
Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.
Copyright © 2025 RACmonitor. Powered by MedLearn Media.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
